EGFR and non-small cell lung carcinoma: Studies have indicated that β2-adrenergic receptors are co-expressed in EGFR-mutant NSCLC cells, thus nullifying LKB1 and enhancing CREB (cyclic adenosine 3′-5′-monophosphate response element-binding protein) and IL-6 activation, and causing resistance to EGFR TKIs.